NOVO NORDISK A/S (NYSE: NVO) INVESTOR ALERT – Investors With Large Losses in Novo Nordisk A/S Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Novo Nordisk A/S, alleging misrepresentations regarding the company's growth potential related to its diabetes/obesity drug, GLP-1, during the period from May 7, 2025, to July 28, 2025 [1][2]. Group 1 - The lawsuit is on behalf of investors who purchased or acquired Novo Nordisk's securities within the specified timeframe [1]. - Defendants are accused of making false statements about the company's growth prospects linked to its GLP-1 drug [2]. - Investors wishing to serve as lead plaintiffs must file by September 30, 2025, and participation does not require serving as lead plaintiff [3]. Group 2 - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has represented large public and private pension funds [4]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [4].